An innovative way to manage myopia in children
The increasing prevalence of myopia in children is a topic that has gained a high level of attention among many, especially the parents of myopic children. By recommending MiYOSMART spectacle lens, you are following an innovative 1 and evidence-based myopia management. Here you can find a summary of all the studies and scientific documentation involving MiYOSMART to date.
Our scientific partner: The Hong Kong Polytechnic University
HOYA Vision Care has worked in close partnership with The Hong Kong Polytechnic University research team since 2014. Together, we developed the innovative1 D.I.M.S. Technology which forms the basis for myopia management with MiYOSMART.
The Hong Kong Polytechnic University has an excellent reputation in the scientific field, with over 30 years of experience in myopia research. It is also one of the Top 100 universities worldwide.2 Six of their scientists are listed among the 200 internationally leading myopia researchers3 In 2002, Professor Chi Ho To and Professor Carly Siu Yin Lam and their research team developed the defocus incorporated soft contact (DISC) lens, one of the pioneering products for myopia control selling across China.4
The theoretical fundamentals: the defocus theory
The defocus theory is the current, internationally accepted theory for explaining induced myopia progression due to single-vision spectacle lenses. This theory is based on various animal and human studies, which confirm that hyperopic defocus increases myopia progression and thus supports myopic peripheral defocus as a therapy option.5
The defocus theory is supported by leading researchers in the guidance from the European Ophthalmological Society and in the International Myopia Institute (IMI) White Paper, IMI - Report on Experimental Models of Emmetropization and Myopia.6-7
Further reading and summaries of the IMI White Papers, as well as their translations, can be found on the IMI website8
Current MiYOSMART research: scientific evidence for effectiveness and safety
The Hong Kong Polytechnic University carried out two studies demonstrating the effectiveness and safety of MiYOSMART lenses: a 2-year, randomised double-blind study and a 3-year follow-up study, which were published in the reputable British Journal of Ophthalmology.9-10 These studies are open to the public, so everyone can access the research.
Subsequently, the data from the 6-year follow-up study was published in spring of 2023 in Scientific Reports. The data showed that over six years, the control effect was sustained and there was no rebound effect in the children who stopped wearing MiYOSMART.11
Recently, a new observational study in the UK demonstrated effectiveness in Caucasian children over a 12-month period, particularly in 10‒15 year olds.12 A full publication of the 2-year results is due to be released in 2024. Additionally, one-year data from an independent randomised controlled trial in China has been presented at the ARVO 2023 conference.13
Further studies verified the safety and tolerability of MiYOSMART, and the properties of D.I.M.S. Technology:
Myopia control options: MiYOSMART comparison with other myopia management solutions
Two papers published in 2021, Efficacy in myopia control and Myopia treatment and prophylaxis with defocus incorporated multiple segments spectacle lenses discuss the effectiveness of MiYOSMART compared with other options in myopia management.21-22
Acceptance Worldwide and in Europe
The World Society of Pediatric Ophthalmology and Strabismus and the IMI endorsed MiYOSMART spectacle lenses with D.I.M.S. Technology as an effective myopia management solution.23-24 Update and guidance on management of myopia from the European Society of Ophthalmology is the most recent reference for myopia management in Europe.6
Conclusion: MiYOSMART is a safe and effective method of myopia management in children9-11
More than four million MiYOSMART spectacle lenses have been sold across the world with the innovative D.I.M.S. Technology.1,25 The successes of this new method are continuously observed and evaluated by eye specialists, the affected families and the scientific community. The currently published research results from the various sources support MiYOSMART as an effective method for slowing down myopia progression.9-11
Further clinical studies are currently running. As soon as results are published, we will update our documentation and inform you. Our experts are happy to provide further information and are available to exchange of experiences.